. 2015 Mar 31;4:152. doi: 10.1186/s40064-015-0929-3

Table 1.

Baseline patient characteristics at the beginning of chemotherapy by treatment arm

Characteristics	Platinum combination therapy (n = 24)	Docetaxel monotherapy (n = 61)	p value
Sex
Male	22	52	0.40^a
Female	2	9
Age, median (range), years	63.5 (46–74)	65 (42–77)	0.78^b
Performance status
0	9	23	0.24^a
1	15	34
2	0	4
Clinical stage at the time of recurrence
III	8	27	0.35^a
IV	16	34
Histology
Adenocarcinoma	14	29	0.06^a
Squamous cell carcinoma	8	28
Large cell carcinoma	2	1
Others	0	3
EGFR mutation status
Mutant	3	8	0.51^a
Wild-type	8	13
Unknown	13	40
Smoking history
Current or former	20	45	0.44^a
Never	3	9
Unknown	1	7
Number of treatment cycles, median (range)	2 (1–6)	2 (1–9)	0.50^b
Response to prior chemoradiotherapy
Complete response	1	0	<0.05^a
Partial response	10	47
Stable disease	10	14
Progressive disease	3	0
Time since prior chemoradiotherapy
<6 months	10	19	0.36^a
≥6 months	14	42
Radiation dosage, median (range), Gy	60 (58–70)	60 (40–74)	0.52^b
Prior chemotherapy regimen
CDDP + VNR	5	20	0.17^a
CDDP + S1	7	16
CBDCA + PTX	6	17
Others	6	8
Number of regimens after progression following second-line chemotherapy
0/1/2/≥3	11/10/3/0	12/22/12/15
Median (range)	1 (0–2)	1 (0–6)	<0.05^b

Abbreviations: EGFR, epidermal growth factor receptor; CDDP, cisplatin; VNR, vinorelbine; CBDCA, carboplatin; PTX, paclitaxel.

^aFisher’s exact test; ^b Wilcoxon rank-sum test.